• 1. One-shot versus stepwise gas–solid synthesis of iron trifluoride: investigation of pure molecular F2 fluorination of chloride precursors
  Nicolas Louvain,Ahmed Fakhry,Pierre Bonnet,Malika El-Ghozzi,Katia Guérin,Moulay-Tahar Sougrati,Jean-Claude Jumas,Patrick Willmann CrystEngComm 2013 15 3664
• 2. pH-responsive magnetic micelles gelatin-g-poly(NIPAAm-co-DMAAm-co-UA)-g-dextran/Fe3O4 as a hydrophilic drug carrier
  Chao-Ming Su,Chen-Yu Huang,Yao-Li Chen,Tzong-Rong Ger RSC Adv. 2017 7 28207
• 3. Iron-based single-atom electrocatalysts: synthetic strategies and applications
  Qinglei Liu,Yongfei Wang,Zhizhi Hu,Zhiqiang Zhang RSC Adv. 2021 11 3079
• 4. Degradable Fe3O4-based nanocomposite for cascade reaction-enhanced anti-tumor therapy
  Yang Wang,Xun Li,Yuan Fang,Jianhua Wang,Danhong Yan,Baisong Chang RSC Adv. 2023 13 7952
• 5. Magnetic and radio-labeled bio-hybrid scaffolds to promote and track in vivo the progress of bone regeneration
  Elisabetta Campodoni,Marisela Velez,Eirini Fragogeorgi,Irene Morales,Patricia de la Presa,Dimitri Stanicki,Samuele M. Dozio,Stavros Xanthopoulos,Penelope Bouziotis,Eleftheria Dermisiadou,Maritina Rouchota,George Loudos,Pilar Marín,Sophie Laurent,Sébastien Boutry,Silvia Panseri,Monica Montesi,Anna Tampieri,Monica Sandri Biomater. Sci. 2021 9 7575

• Catalysts and Inorganic Chemicals Inorganic Compounds Mixed metal/non-metal compounds Transition metal salts Transition metal chlorides
• Catalysts and Inorganic Chemicals Inorganic Compounds Salt
• Catalysts and Inorganic Chemicals Inorganic Compounds

Recent Advances in the Application of Iron(II) Chloride Tetrahydrate (CAS 13478-10-9) in Chemical Biology and Pharmaceutical Research

Iron(II) Chloride Tetrahydrate (FeCl?·4H?O, CAS 13478-10-9) has emerged as a versatile reagent in chemical biology and pharmaceutical research due to its unique redox properties and biocompatibility. Recent studies have highlighted its applications in catalysis, drug synthesis, and biomedical imaging. This research brief synthesizes the latest findings on the compound's role in these areas, providing insights into its mechanistic contributions and potential therapeutic benefits.

A 2023 study published in Journal of Medicinal Chemistry demonstrated the efficacy of Iron(II) Chloride Tetrahydrate as a catalyst in the synthesis of novel heterocyclic compounds with anticancer activity. The researchers utilized FeCl?·4H?O to facilitate a key oxidative cyclization step, achieving yields of up to 92% under mild conditions. This methodology offers a sustainable alternative to traditional palladium-based catalysts, aligning with green chemistry principles.

In the field of biomedical imaging, Iron(II) Chloride Tetrahydrate has shown promise as a contrast agent precursor. A team at MIT developed a nanoparticle system incorporating FeCl?·4H?O that exhibited enhanced magnetic resonance imaging (MRI) contrast properties while maintaining low cytotoxicity. The study, published in ACS Nano, reported a 40% improvement in T2-weighted image contrast compared to conventional iron oxide nanoparticles.

Recent investigations into the compound's biological interactions have revealed novel mechanisms of action. Research from the University of Cambridge identified Iron(II) Chloride Tetrahydrate as a modulator of hypoxia-inducible factor (HIF) signaling pathways. The study demonstrated that controlled release of Fe2? ions from the compound could stabilize HIF-1α under normoxic conditions, suggesting potential applications in ischemia treatment and regenerative medicine.

Quality control advancements for Iron(II) Chloride Tetrahydrate have also been reported. A 2024 analytical chemistry study established a novel HPLC-MS method for detecting trace impurities in pharmaceutical-grade FeCl?·4H?O, achieving detection limits below 0.1 ppm. This development addresses previous challenges in ensuring batch-to-batch consistency for critical research applications.

Looking forward, the pharmaceutical industry is exploring Iron(II) Chloride Tetrahydrate's potential in combination therapies. Preliminary data from Pfizer's oncology division indicates synergistic effects when FeCl?·4H?O is co-administered with certain checkpoint inhibitors, potentially enhancing tumor immunogenicity. Clinical trials are expected to begin in late 2024 to evaluate this approach in solid tumors.

• 21645-51-2(Aluminum hydroxide)
• 1345-25-1(Iron(II) oxide)
• 10257-54-2(Copper sulfate monohydrate)
• 7720-78-7(Ferrous sulfate)
• 1332-37-2(Iron(III) oxide)
• 7758-94-3(Iron(II) Chloride)
• 1309-33-7(Iron hydroxide)
• 12125-02-9(Ammonium chloride)
• 20427-59-2(Copper Hydroxide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)